Key result
In isolated rat arteries, apixaban enhanced vasodilation mediated by the PAR-2 agonist SLIGRL, likely by inhibiting PAR-2 desensitization induced by endogenous FXa.
Why the study?
Does apixaban enhance PAR-2-mediated vasodilatation in isolated rat arteries?
Does apixaban enhance PAR-2-mediated vasodilatation in isolated rat arteries?
Apixaban enhances PAR-2-mediated vasodilatation by inhibiting FXa, which may protect PAR-2 from desensitization and potentially improve endothelial function.
Answers are grounded in this paper and cite their sources.
Should not change practice; leaves open whether apixaban's PAR-2 effects translate to human endothelial benefit.
Apixaban (APX) is a direct inhibitor of factor X (FXa) approved for prophylaxis and treatment of deep venous thrombosis and atrial fibrillation. Because FXa activates protease-activated receptor 2 (PAR-2) in endothelium and vascular smooth muscle, inhibition of FXa by APX may affect vasomotor function. The effect of APX was assessed in vitro, by wire myography, in rat mesenteric resistance arteries (MRA) and basilar arteries (BA) challenged with vasoconstrictors (phenylephrine, PE; 5-hydroxytryptamine, 5-HT), vasodilators (acetylcholine, ACh; sodium nitroprusside, SNP) or with the PAR-2 peptide agonist SLIGRL. APX (10 M) reduced the vasoconstriction to PE and 5-HT while did not change the vasodilatation to ACh or SNP. SLIGRL induced concentration-dependent vasodilation in pre-constricted arteries, that was reduced by incubation with the NO inhibitor NG-nitro-L-arginine (L-NNA) and abolished by endothelium removal. APX enhanced vasodilation to SLIGRL either in the presence or in the absence of L-NNA, but was ineffective in endothelium-denuded vessels. In preparations from heparin-treated rats (to inhibit FXa) APX did not change the vasodilation to SLIGRL. FXa enzymatic activity, detected in mesentery homogenates from controls, was inhibited by APX, whereas APX-sensitive enzymatic activity was undetectable in homogenates from heparin-treated rats. Immunoblot analysis showed that incubation of MRA or aorta with APX increased the abundance of PAR-2, an effect not seen in MRA from heparin-treated rats or in endothelium-denuded aortas. In conclusion, inhibition of FXa by APX increases vasodilatation mediated by PAR-2. APX may act by inhibiting PAR-2 desensitization induced by endogenous FXa. This effect could be useful in the context of endothelial dysfunction associated to cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Villari et al. (2017) studied Healthy (isolated rat arteries). Apixaban vs. Control (vehicle) was evaluated on Maximum vasorelaxation (Emax, % residual tone) to PAR-2 agonist SLIGRL in isolated mesenteric resistance arteries (p=<0.001). In isolated rat arteries, apixaban enhanced vasodilation mediated by the PAR-2 agonist SLIGRL, likely by inhibiting PAR-2 desensitization induced by endogenous FXa.
Synapse has enriched 10 related papers. Consider them for comparative context: